

Griet Glorieux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6052344/publications.pdf>

Version: 2024-02-01

153
papers

9,836
citations

44069

48
h-index

38395

95
g-index

157
all docs

157
docs citations

157
times ranked

7574
citing authors

#	ARTICLE	IF	CITATIONS
1	Potassium and fiber: a controversial couple in the nutritional management of children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2022, , .	1.7	3
2	The Effect of β -Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial. <i>Nutrients</i> , 2022, 14, 805.	4.1	18
3	What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. <i>Toxins</i> , 2022, 14, 221.	3.4	20
4	The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3439.	4.1	28
5	Dietary Advanced Glycation End Products in an Elderly Population with Diabetic Nephropathy: An Exploratory Investigation. <i>Nutrients</i> , 2022, 14, 1818.	4.1	6
6	MO590: A Home-Based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity. The Phoenix-Kidney Study Protocol. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	1
7	The impact of intradialytic cycling on the removal of protein-bound uraemic toxins: A randomised cross-over study. <i>International Journal of Artificial Organs</i> , 2021, 44, 156-164.	1.4	1
8	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 811-818.	0.7	26
9	Dietary Fibre Intake Is Associated with Serum Levels of Uraemic Toxins in Children with Chronic Kidney Disease. <i>Toxins</i> , 2021, 13, 225.	3.4	15
10	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	2.7	47
11	MO460ASSOCIATION BETWEEN CARBAMYLATED ALBUMIN, GUT MICROBIOTA AND THEIR DERIVED METABOLITES IN CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
12	Uremic Toxins and Cardiovascular System. <i>Cardiology Clinics</i> , 2021, 39, 307-318.	2.2	7
13	Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique. <i>Journal of Personalized Medicine</i> , 2021, 11, 949.	2.5	13
14	A low aromatic amino-acid diet improves renal function and prevent kidney fibrosis in mice with chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 19184.	3.3	19
15	Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10549.	4.1	11
16	Dietary fibre intake is low in paediatric chronic kidney disease patients but its impact on levels of gut-derived uraemic toxins remains uncertain. <i>Pediatric Nephrology</i> , 2021, 36, 1589-1595.	1.7	7
17	Free α -cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 998-1005.	0.7	32
18	Gut Microbiome Profiling Uncovers a Lower Abundance of <i>Butyricoccus</i> in Advanced Stages of Chronic Kidney Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 1118.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease. <i>Toxins</i> , 2021, 13, 809.	3.4	8
20	Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 648-656.	0.7	14
21	Uremic toxins promote accumulation of oxidized protein and increased sensitivity to hydrogen peroxide in endothelial cells by impairing the autophagic flux. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 123-129.	2.1	19
22	TO011HEALTH UTILITY BUT NOT UREMIC TOXINS ARE ASSOCIATED WITH ONE YEAR MORTALITY IN HD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
23	Effects of Fecal Microbiota Transplantation on Composition in Mice with CKD. <i>Toxins</i> , 2020, 12, 741.	3.4	42
24	The authors reply. <i>Kidney International</i> , 2020, 98, 784.	5.2	0
25	P0922A LOW AROMATIC AMINO-ACID DIET IMPROVES RENAL FUNCTION AND PREVENTS KIDNEY FIBROSIS IN MICE WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	3
26	Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1986.	4.1	67
27	Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2031.	4.1	17
28	P0703IDENTIFICATION AND QUANTIFICATION OF UREMIC TOXIN PRECURSORS-GENERATING GUT BACTERIA IN CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
29	Comparison of five assays for DNA extraction from bacterial cells in human faecal samples. <i>Journal of Applied Microbiology</i> , 2020, 129, 378-388.	3.1	14
30	Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. <i>Kidney International</i> , 2020, 97, 1230-1242.	5.2	125
31	Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1522.	4.1	12
32	UV Fluorescence-Based Determination of Urinary Advanced Glycation End Products in Patients with Chronic Kidney Disease. <i>Diagnostics</i> , 2020, 10, 34.	2.6	12
33	Carbamoylated Nail Proteins as Assessed by Near-Infrared Analysis Are Associated with Load of Uremic Toxins and Mortality in Hemodialysis Patients. <i>Toxins</i> , 2020, 12, 83.	3.4	4
34	Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 245.	3.4	44
35	Exploring the possibilities of infrared spectroscopy for urine sediment examination and detection of pathogenic bacteria in urinary tract infections. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1759-1767.	2.3	16
36	FO079CONCENTRATIONS OF P-CRESYL - AND INDOXYL SULFATE AND THEIR PRECURSORS IN DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE: FROM FECES TO URINE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0

#	ARTICLE	IF	CITATIONS
37	Selective Transport of Protein-Bound Uremic Toxins in Erythrocytes. <i>Toxins</i> , 2019, 11, 385.	3.4	8
38	Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease. <i>Scientific Reports</i> , 2019, 9, 10236.	3.3	21
39	An in-vitro assay using human spermatozoa to detect toxicity of biologically active substances. <i>Scientific Reports</i> , 2019, 9, 14525.	3.3	5
40	The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds. <i>Journal of Nephrology</i> , 2019, 32, 733-740.	2.0	22
41	Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population. <i>Toxins</i> , 2019, 11, 235.	3.4	20
42	Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. <i>Scientific Reports</i> , 2019, 9, 4477.	3.3	62
43	Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. <i>International Urology and Nephrology</i> , 2019, 51, 293-302.	1.4	25
44	Gut microbiota dynamics and uraemic toxins: one size does not fit all. <i>Gut</i> , 2019, 68, 2257.1-2260.	12.1	37
45	A plea for more uremic toxin research in children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 921-924.	1.7	8
46	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2156-2164.	0.7	46
47	Urea and chronic kidney disease: the comeback of the century? (in uraemia research). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 4-12.	0.7	122
48	Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 489-496.	0.7	12
49	Early and asymptomatic cardiac dysfunction in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 450-458.	0.7	21
50	Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 315-323.	1.7	15
51	Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease. <i>Toxins</i> , 2018, 10, 520.	3.4	21
52	FP276VALUE OF URINARY PROTEOME-BASED CLASSIFIER ASSOCIATED WITH CHRONIC KIDNEY DISEASE AND ITS PROGRESSION IN THE PROGNOSIS OF A PATIENT-RELEVANT ENDPOINT, MORTALITY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i124-i125.	0.7	0
53	Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. <i>Toxins</i> , 2018, 10, 33.	3.4	218
54	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018, 10, 237.	3.4	28

#	ARTICLE	IF	CITATIONS
55	Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up. <i>BMC Nephrology</i> , 2018, 19, 1.	1.8	91
56	Gut-Derived Metabolites and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1311-1313.	4.5	6
57	SP380ENDOTHELIAL GLYCOCALYX DAMAGE IN CKD: ROLE OF THE UREMIC TOXIN INDOXYL SULFATE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i474-i474.	0.7	0
58	Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 978-986.	0.7	15
59	Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 436-440.	2.3	15
60	Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2201-2211.	3.7	32
61	Effect of sample temperature, pH, and matrix on the percentage protein binding of protein-bound uraemic toxins. <i>Analytical Methods</i> , 2017, 9, 1935-1940.	2.7	11
62	Exploring binding characteristics and the related competition of different protein-bound uremic toxins. <i>Biochimie</i> , 2017, 139, 20-26.	2.6	19
63	Quantification of carbamylated albumin in serum based on capillary electrophoresis. <i>Electrophoresis</i> , 2017, 38, 2135-2140.	2.4	11
64	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.8	77
65	p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 2000-2009.	0.7	24
66	p -cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. <i>Kidney International</i> , 2017, 92, 1323-1324.	5.2	22
67	The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis. <i>Contributions To Nephrology</i> , 2017, 191, 168-177.	1.1	3
68	SP777TAILORED IMMUNOSUPPRESSION IN DE NOVO RENAL TRANSPLANTATION BASED ON IMMUNE FUNCTION MONITORING: A RANDOMISED CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii406-iii406.	0.7	0
69	p-Cresyl Sulfate. <i>Toxins</i> , 2017, 9, 52.	3.4	262
70	Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients. <i>PLoS ONE</i> , 2017, 12, e0186010.	2.5	25
71	Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. <i>Toxins</i> , 2016, 8, 149.	3.4	26
72	Response to Tsikas et al. Comments on Boelaert et al. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. <i>Toxins</i> 2016, 8, 149. <i>Toxins</i> , 2016, 8, 312.	3.4	0

#	ARTICLE	IF	CITATIONS
73	Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis. PLoS ONE, 2016, 11, e0147159.	2.5	45
74	Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole and pilocarpine-induced seizures in mice. Epilepsia, 2016, 57, e146-50.	5.1	3
75	Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes and Endocrinology, 2016, 4, 360-373.	11.4	78
76	Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?. Nephrology Dialysis Transplantation, 2016, 31, 1547-1551.	0.7	11
77	Development of a MALDI MS-based platform for early detection of acute kidney injury. Proteomics - Clinical Applications, 2016, 10, 732-742.	1.6	13
78	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. Circulation Journal, 2016, 80, 722-730.	1.6	28
79	New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Scientific Reports, 2016, 6, 34429.	3.3	58
80	Uric acid is released in the brain during seizure activity and increases severity of seizures in a mouse model for acute limbic seizures. Experimental Neurology, 2016, 277, 244-251.	4.1	14
81	Association of advanced age with concentrations of uraemic toxins in CKD. Journal of Nephrology, 2016, 29, 81-91.	2.0	10
82	Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Toxins, 2015, 7, 3933-3946.	3.4	105
83	Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. Frontiers in Medicine, 2015, 2, 60.	2.6	52
84	Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial. PLoS ONE, 2015, 10, e0128634.	2.5	18
85	Once upon a time in dialysis: the last days of Kt/V?. Kidney International, 2015, 88, 460-465.	5.2	67
86	Protein-bound solute removal during extended multipass versus standard hemodialysis. BMC Nephrology, 2015, 16, 57.	1.8	9
87	Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?. Nephrology Dialysis Transplantation, 2015, 30, 943-951.	0.7	25
88	Development and validation of an ultra-high performance liquid chromatography tandem mass spectrometry method to measure creatinine in human urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 988, 88-97.	2.3	29
89	Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy. CKJ: Clinical Kidney Journal, 2015, 8, 353-362.	2.9	25
90	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrology Dialysis Transplantation, 2015, 30, 1842-1852.	0.7	64

#	ARTICLE	IF	CITATIONS
91	Protein-bound uraemic toxins, dicarbonyl stress and advanced glycation end products in conventional and extended haemodialysis and haemodiafiltration. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1395-1402.	0.7	52
92	The intestine and the kidneys: a bad marriage can be hazardous. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 168-179.	2.9	82
93	New Methods and Technologies for Measuring Uremic Toxins and Quantifying Dialysis Adequacy. <i>Seminars in Dialysis</i> , 2015, 28, 114-124.	1.3	29
94	Transcriptome Analysis in Patients with Chronic Kidney Disease on Hemodialysis Disclosing a Key Role for CD16+CX3CR1+ Monocytes. <i>PLoS ONE</i> , 2015, 10, e0121750.	2.5	13
95	Soluble Tumor Necrosis Factor Receptor 1 and 2 Predict Outcomes in Advanced Chronic Kidney Disease: A Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0122073.	2.5	59
96	p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 56-64.	0.7	77
97	Nonextracorporeal Methods for Decreasing Uremic Solute Concentration: A Future Way To Go?. <i>Seminars in Nephrology</i> , 2014, 34, 228-243.	1.6	25
98	The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1897-1907.	6.1	525
99	Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialysis fluid. <i>Scientific Reports</i> , 2014, 4, 6390.	3.3	9
100	A novel UPLC-MS/MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1937-1947.	3.7	47
101	Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma. <i>Biomaterials</i> , 2013, 34, 7819-7828.	11.4	124
102	Uremia-Related Oxidative Stress in Leukocytes Is Not Triggered by β_2 -Microglobulin. , 2013, 23, 456-463.		9
103	Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 142-150.	3.8	105
104	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1981-1994.	6.1	96
105	An update on uremic toxins. <i>International Urology and Nephrology</i> , 2013, 45, 139-150.	1.4	134
106	p-Cresyl Sulfate Promotes Insulin Resistance Associated with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 88-99.	6.1	216
107	Does the Adequacy Parameter Kt/Vurea Reflect Uremic Toxin Concentrations in Hemodialysis Patients?. <i>PLoS ONE</i> , 2013, 8, e76838.	2.5	64
108	Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?. <i>PLoS ONE</i> , 2013, 8, e67168.	2.5	60

#	ARTICLE	IF	CITATIONS
109	Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2388-2396.	0.7	97
110	Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. <i>Kidney International</i> , 2012, 82, 1297-1303.	5.2	134
111	Dialysis water and fluid purity: more than endotoxin. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4010-4021.	0.7	45
112	Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease. <i>PLoS ONE</i> , 2012, 7, e44201.	2.5	29
113	Prognostic Implications of Plasma Myoglobin Levels in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2012, 35, 959-968.	1.4	1
114	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	4.5	119
115	Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 955-963.	0.7	57
116	Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2624-2630.	0.7	91
117	Warning: the unfortunate end of p-cresol as a uraemic toxin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1464-1467.	0.7	86
118	Prospective Evaluation of the Change of Predialysis Protein-Bound Uremic Solute Concentration With Postdilution Online Hemodiafiltration. <i>Artificial Organs</i> , 2010, 34, 580-585.	1.9	66
119	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. <i>Blood Purification</i> , 2010, 30, 277-287.	1.8	49
120	The Gut: The Forgotten Organ in Uremia?. <i>Blood Purification</i> , 2010, 29, 130-136.	1.8	139
121	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1183-1191.	0.7	371
122	Uremic Toxins. , 2010, , 219-234.		0
123	Uremic Toxins. , 2010, , 21-31.		1
124	Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1429-1435.	0.7	124
125	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. <i>Seminars in Dialysis</i> , 2009, 22, 323-328.	1.3	27
126	PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins. <i>Seminars in Dialysis</i> , 2009, 22, 340-345.	1.3	103

#	ARTICLE	IF	CITATIONS
127	PROGRESS IN UREMIC TOXIN RESEARCH: Platelet/Leukocyte Activation, Inflammation, and Uremia. Seminars in Dialysis, 2009, 22, 423-427.	1.3	42
128	PROGRESS IN UREMIC TOXIN RESEARCH: Uremic Toxins in Acute Kidney Injury. Seminars in Dialysis, 2009, 22, 445-448.	1.3	30
129	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1551-1558.	4.5	740
130	Metabolic Waste Products in Acute Uremia. , 2009, , 1093-1097.		0
131	Evolution of protein-bound uraemic solutes during predilution haemofiltration. Journal of Nephrology, 2009, 22, 352-7.	2.0	22
132	What is new in uremic toxicity?. Pediatric Nephrology, 2008, 23, 1211-1221.	1.7	182
133	Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrology Dialysis Transplantation, 2008, 24, 562-570.	0.7	156
134	Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. CKJ: Clinical Kidney Journal, 2008, 1, 2-10.	2.9	11
135	Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney International, 2008, 73, 765-770.	5.2	175
136	Uremic Toxins: Do We Know Enough to Explain Uremia?. Blood Purification, 2008, 26, 77-81.	1.8	32
137	A Bench to Bedside View of Uremic Toxins. Journal of the American Society of Nephrology: JASN, 2008, 19, 863-870.	6.1	287
138	A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrology Dialysis Transplantation, 2008, 24, 548-554.	0.7	29
139	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrology Dialysis Transplantation, 2007, 22, 3381-3390.	0.7	74
140	Uremic toxins in chronic renal failure. Prilozi / Makedonska Akademija Na Naukite I Umetnostite, Oddelenie Za Bioloiki I Medicinski Nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2007, 28, 173-204.	0.2	3
141	P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation, 2006, 22, 592-596.	0.7	259
142	Uremic Toxins in Chronic Renal Failure. , 2006, , 71-103.		3
143	In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney International, 2004, 65, 2184-2192.	5.2	92
144	In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney International, 2004, 66, 1873-1880.	5.2	53

#	ARTICLE	IF	CITATIONS
145	P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. <i>Thrombosis and Haemostasis</i> , 2004, 92, 140-150.	3.4	85
146	Review on uremic toxins: Classification, concentration, and interindividual variability. <i>Kidney International</i> , 2003, 63, 1934-1943.	5.2	1,379
147	New insights in uremic toxins. <i>Kidney International</i> , 2003, 63, S6-S10.	5.2	174
148	Uraemic retention and apoptosis: what is the balance for the inflammatory status in uraemia?. <i>European Journal of Clinical Investigation</i> , 2003, 33, 631-634.	3.4	27
149	Low water-soluble uremic toxins. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 257-269.	2.1	21
150	Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1648-1653.	0.7	12
151	Advanced glycation and the immune system: stimulation, inhibition or both?. <i>European Journal of Clinical Investigation</i> , 2001, 31, 1015-1018.	3.4	7
152	Inhibition of calcitriol-induced monocyte CD14 expression by uremic toxins: role of purines.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 1826-1831.	6.1	23
153	Effect of simplified dietary advice on nutritional status and uremic toxins in chronic kidney disease participants. <i>South African Journal of Clinical Nutrition</i> , 0, , 1-9.	0.7	2